Background: Postoperative acute kidney injury (AKI) is frequent and associated with adverse outcomes. Unfortunately, the early diagnosis of AKI remains a challenge. Combining functional and tubular damage biomarkers may provide better precision for AKI detection. However, the diagnostic accuracy of this combination for AKI after neurosurgery is unclear. Serum cystatin C (sCysC) and urinary albumin/creatinine ratio (uACR) are considered functional bio-markers, while urinary N-acetyl-β-D-glucosaminidase (uNAG) represents tubular damage. We aimed to assess the performances of these clinical available biomarkers and their combinations for AKI prediction after resection of intracranial space-occupying lesions. Methods: A prospective study was conducted, enrolling adults undergoing resection of intracranial spaceoccupying lesions and admitted to the neurosurgical intensive care unit. The discriminative abilities of postoperative sCysC, uNAG, uACR, and their combinations in predicting AKI were compared using the area under the receiver operating characteristic curve (AUC-ROC), continuous net reclassification index (cNRI), and incremental discrimination improvement (IDI). Results: Of 605 enrolled patients, AKI occurred in 67 patients. The cutoff values of sCysC, uNAG, and uACR to predict postoperative AKI were 0.72 mg/L, 19.98 U/g creatinine, and 44.21 mg/g creatinine, respectively. For predicting AKI, the composite of sCysC and uNAG (AUC-ROC = 0.785) outperformed either individual biomarkers or the other two panels (uNAG plus uACR or sCysC plus uACR). Adding this panel to the predictive model improved the AUC-ROC to 0.808. Moreover, this combination significantly improved risk reclassification over the clinical model alone, with cNRI (0.633) and IDI (0.076). Superior performance of this panel was further confirmed with bootstrap internal validation. Conclusions: Combination of functional and tubular damage biomarkers improves the predictive accuracy for AKI after resection of intracranial space-occupying lesions.
Introduction
Acute kidney injury (AKI) is a frequent complication in the postsurgical population and associated with longer length of stay, significantly higher costs, and increased rates of mortality and morbidity [1, 2] . Early identification of AKI is crucial to guide management. Unfortunately, AKI represents a multifactorial and complex clinical condition, and thus early diagnosis of postoperative AKI remains a challenge. Accordingly, the Acute Dialysis Quality Initiative (ADQI) working group recommended a combination of functional and tubular damage biomarkers for detecting AKI, which reflects different underlying pathological processes of AKI [3] . Recently, combining functional and tubular damage biomarkers was reported as an effective clinical strategy for detecting AKI, including patients after cardiac surgery [4, 5] or patients suffering from heart failure [6] . However, limited data are available regarding the prognostic utility of the abovementioned composite in predicting AKI after neurosurgery, which is a well-known high-risk surgery.
Urinary N-acetyl-β-D-glucosaminidase (uNAG) is a tubular damage biomarker [7, 8] , while serum cystatin C (sCysC) and urinary albumin/creatinine ratio (uACR) are glomerular filtration biomarkers [7] . Besides, these clinically available biomarkers are considered markers for AKI detection worldwide [7] [8] [9] [10] [11] [12] [13] . On this ground, we conducted a prospective, observational study in an adult neurological intensive care unit (ICU) to assess the performance of combinations of these biomarkers for AKI prediction in patients undergoing resection of intracranial space-occupying lesions.
Patients and Methods

Patient Population
The prospective observational study was conducted in a neurosurgical ICU of a tertiary care hospital. All patients (aged 18 years or older) who underwent resection of intracranial space-occupying lesions and were admitted to the neurosurgical ICU between October 2014
Outcome and Definitions
The outcome was the occurrence of AKI within 72 h after surgery. AKI was defined according to the Kidney Disease: Improving Global Outcomes (KDIGO) criteria for AKI [23] as any of the following: increase in sCr by ≥0.3 mg/dL (≥26.5 µmol/L) within 48 h, or increase in sCr to ≥1.5 times baseline within 1 week, or urine output < 0.5 mL/kg/h for 6 h. AKI is staged according to the following KDIGO criteria. Stage 1: increase of sCr to 1.5-1.9 times from baseline, or ≥0.3 mg/dL (≥26.5 µmol/L) increase of sCr, or urine output < 0.5 mL/kg/h for 6-12 h. Stage 2: increase of sCr to 2.0-2.9 times from baseline or urine output < 0.5 mL/ kg/h for ≥12 h. Stage 3: increase of sCr to 3.0 times from baseline, or ≥4.0 mg/dL (≥353.6 µmol/L) increase of sCr, or initiation of renal replacement therapy, or urine output < 0.3 mL/ kg/h for ≥24 h, or anuria for ≥12 h.
Baseline creatinine was determined by using the following rules ranked in descending order of preference as previously described [24] : (1) the most recent pre-ICU value between 30 and 365 days before ICU admission (n = 52); (2) a stable pre-ICU value > 365 days for patients aged < 40 years (stable defined as within 15% of the lowest ICU measurement) before ICU admission (n = 3); (3) pre-ICU value > 365 days before ICU admission and less than the initial sCr on ICU admission (n = 12); (4) pre-ICU value (between 3 and 39 days before ICU admission) less than or equal to the initial on-admission sCr to ICU and not obviously in AKI (n = 351); (5) the lowest initial on-admission sCr to ICU (n = 81), the last ICU value (n = 56), or the minimum value at follow-up to 365 days (n = 50).
Statistical Analysis
We calculated that the postoperative AKI rate in patients who underwent resection of intracranial space-occupying lesion was 12%, which we determined in a chart review (unpublished). Based on a previous study described by Hanley and McNeil [25] , we estimated that a sample size of 573 patients was required, with a two-sided test (α error = 5%; power = 90%). Considering a possible dropout rate of 10%, we would need approximately 630 cases.
SPSS version 13.0 for Windows (SPSS Inc., Chicago, IL, USA), R version 3.3.0 for Windows (R Foundation for Statistical Computing, Vienna, Austria), and MedCalc version 12.5.0 for Windows (MedCalc Software, Ostend, Belgium) were used to complete the analysis. Continuous variables were expressed as medians with interquartile range or mean ± standard deviation. Categorical variables were expressed as number (percentage). To compare the nonnormally distributed continuous variables, the Wilcoxon rank-sum test was used. The categorical variables were compared by the χ 2 or the Fisher exact test. The renal biomarkers displayed nonnormal distributions, and thus the Spearman correlation was used to assess the correlation. Based on a previous report [26] , we described the correlation coefficient using the following values: 0.90-1.0 = very strong, 0.70-0.89 = strong, 0.40-0.69 = moderate, 0.10-0.39 = weak, and 0.00-0.09 = negligible correlation. The receiver operating characteristic (ROC) curves with their area under the ROC curve (AUC-ROC) were calculated. The comparison of AUC-ROC between the groups was conducted with the method of to DeLong et al. [27] , and the combination with the highest AUC-ROC was included in the subsequent analyses. The sensitivity, specificity, positive and negative predictive values, and positive and negative likelihood ratios of the biomarkers were also analyzed. The optimal cutoff values for AKI detection were defined for individual biomarkers and their combinations according to the Youden index [28] . We conducted uni-and multivariate logistic regression to construct the clinical model for postoperative AKI. The clinical perioperative variables with p < 0.10 in univariate analysis were all included in the multivariate analysis. Logistic multivariate forward stepwise (likelihood ratio) regression was then used to construct the clinical risk prediction model. The odds ratio and 95% confidence interval were calculated. The performance of the optimal panel combining with the clinical model was assessed by AUC-ROC, incremental discrimination improvement (IDI), and net reclassification index (NRI), as described previously [29, 30] . The NRI and IDI are the extensions of the reclassification idea [30, 31] . The NRI [30] mainly focuses on reclassification tables which are constructed separately for patients with and without event. The NRI calculates the correct movement in the categories "upwards" for patients with event and "downwards" for patients without event. For patients with event, any "upward" movement indicates improved reclassification, whereas any "downward" movement implies worse reclassification. For patients without event, the interpretation is opposite. Thus, the NRI is the sum of the improvement in reclassification. Here, the continuous NRI (cNRI) was calculated. On the other hand, IDI mainly focuses on the differences between integrated (average) sensitivities and "one minus specificities" for risk models with and without adding new markers. Thus, IDI is the value to integrate all the NRI possible cutoffs for the event's probability. The performance of the optimal panel for AKI prediction was internally validated by a bootstrap method with 1,000 replications [32] . All tests were two-tailed, and p < 0.05 was considered statistically significant.
Results
Baseline Characteristics and Outcomes of Patients
Of the 648 consecutive patients who were screened for inclusion in the study, 43 (6.6%) were excluded ( Fig. 1 ). For the analyses, 605 patients were enrolled. The baseline characteristics and outcomes of patients are summarized in Table 1 . Overall, AKI based on the KDIGO criteria occurred in 67 patients (11.1%) within the first 72 h after surgery. Of these AKI patients, 60 (89.6%) were at stage 1 and 7 (10.4%) at stage 2. Compared with the non-AKI patients, the AKI patients were older. Emergency surgery was done most in the AKI group (16.4 vs. 1.7%, p < 0.001). Additionally, patients with AKI had higher American Society of Anesthesiologists classification scores and were treated with more mannitol preoperatively compared to patients without AKI. However, AKI patients did not take more nephrotoxic drugs preoperatively than non-AKI patients. There was no significant difference in preoperative application of radiographic contrast between patients with and without AKI. Baseline sCr and eGFR were similar for the two groups.
Notably, patients who experienced AKI were more likely to suffer adverse outcomes. AKI occurrence was associated with a higher rate of ICU and in-hospital mortality, postoperative tracheotomy, higher costs, longer ICU and hospital length of stay, and prolonged duration of postoperative mechanical ventilation. Continuous variables are expressed as mean ± standard deviation or median (25th to 75th percentile, interquartile range). Categorical variables are expressed as a n (%). AKI, acute kidney injury; ASA, American Society of Anesthesiologists; CNY, Chinese yuan; eGFR, estimated glomerular filtration rate; GCS, Glasgow Coma Scale; ICSOL, intracranial space-occupying lesion; ICU, intensive care unit. a Includes any of the following medications administered within 5 days before operation: angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, nonsteroidal anti-inflammatory drug, immunosuppressant, aminoglycoside, vancomycin, acyclovir, amphotericin, allopurinol, or colistin. b Includes hemangioblastoma, cavernous hemangioma, embryonal dysplastic neuroepithelial tumor, primitive neuroectodermal tumor brain, abscess, cyst, or cholinoma. Table 2 depicts the intra-and postoperative characteristics of patients with and without AKI. Compared with patients without AKI, patients with AKI had higher postoperative APACHE II and GCS scores and higher concentrations of postoperative sCr, sCysC, uNAG, and uACR. In our cohort, patients with AKI were treated with more mannitol after operation compared to patients without AKI. AKI patients were more likely to undergo reoperation. The percentage of patients who received surgery involving the supratentorial region was significantly higher in the AKI than the non-AKI group (p = 0.028).
Intra-and Postoperative Characteristics of the Patients
The median concentrations of pre-and postoperative serum sodium were 139.8 and 140.9 mmol/L, respectively, while the median concentrations of pre-and postoperative serum potassium were 3.9 and 3.6 mmol/L, respectively (Tables 1, 2). Compared to non-AKI patients, patients with AKI had higher levels of postoperative serum potassium (p = 0.002). Furthermore, the Δ serum potassium was significantly larger in the non-AKI group (-0.31 [-0.58, 0.01]) than that in the AKI group (-0.11 [-0.42, 0.18]) (p = 0.001). In addition, Δ serum potassium showed a significant but negligible correlation with baseline eGFR, while there was no significant correlation between Δ serum sodium and baseline eGFR (online suppl. Table 1 ; for all online suppl. material, see www.karger.com/doi/10.1159/000504599). Similarly, Δ serum potassium had a weak correlation with postoperative sCr (r = 0.166, p < 0.01). Continuous variables are expressed as mean ± standard deviation or median (25th to 75th percentile, interquartile range). Categorical variables are expressed as a n (%). AKI, acute kidney injury; APACHE, Acute Physiology and Chronic Health Evaluation; GCS, Glasgow Coma Scale; sCysC, serum cystatin C; uACR, urinary albumin-creatinine ratio; uNAG, urinary N-acetyl-β-D-glucosaminidase; UP, urine production within the first 24 h after operation; Δ, change from first post-to preoperative check. a Includes any of the following medications administered within 3 days after operation: angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, nonsteroidal anti-inflammatory drug, immunosuppressant, aminoglycoside, vancomycin, acyclovir, amphotericin, allopurinol, or colistin. b Reoperation within 3 days after the first surgery. 
Predictive Abilities of Individual Biomarkers and Their Combinations for Postoperative AKI Development
Among the three biomarkers, the correlation between sCysC and baseline eGFR was strongest (r = -0.308, p < 0.01) (online suppl. Table 2 ). Similarly, sCysC displayed a moderate correlation with postoperative sCr (r = 0.470, p < 0.01).
The ROC curve analysis demonstrated that the three clinical biomarkers predicted postoperative AKI with statistical significance (Table 3 ). There was no significant difference in AUC-ROC between sCysC and uNAG or between uNAG and uACR, but the AUC-ROC was statistically higher for sCysC than uACR (p = 0.028). We then developed the possible panels consisting of these biomarkers to assess their predictive ability (sCysC plus uNAG, uNAG plus uACR, and sCysC plus uACR). The AUC-ROC for postoperative AKI yielded superior performance by the panel of sCysC plus uNAG than by either the individual biomarkers or the other two panels (uNAG plus uACR and sCysC plus uACR) ( Table 3 ; Fig. 2) . Consequently, the combination of sCysC plus uNAG was chosen for the subsequent analyses.
In addition, the AUC-ROC of the combination of uNAG and sCysC for predicting postoperative AKI within the first 24 h after operation was 0.828 (0.765-0.890), its AUC-ROC within AKI, acute kidney injury; APACHE, Acute Physiology and Chronic Health Evaluation; ASA, American Society of Anesthesiologists; CI, confidence interval; GCS, Glasgow Coma Scale; OR, odds ratio; Δ, change from first post-to preoperative check. a Hemangioblastoma, cavernous hemangioma, embryonal dysplastic neuroepithelial tumor, primitive neuroectodermal tumor brain, abscess, cyst, or cholinoma. b Reoperation within 3 days after the first surgery. Table 3 ).
The performance of sCysC plus uNAG was further confirmed by bootstrap internal validation, in which the average AUC-ROC value for predicting postoperative AKI was 0.787 (0.739-0.836).
Relative Contribution of the Combination of sCysC and uNAG to the Clinical Model for Postoperative AKI Prediction
To determine the added contribution of the combination of sCysC and uNAG to the clinical model for postoperative AKI prediction, logistic regression analysis was performed. The clinical model for AKI prediction included age, postoperative sCr concentration, and postoperative GCS score ( Table 4 ).
The panel of sCysC plus uNAG was then added to the abovementioned model ( Table 5 ). The clinical model could predict postoperative AKI with reasonable certainty (AUC-ROC = 0.759). The AUC-ROC of this clinical model was significantly improved to 0.808 with the addition of sCysC plus uNAG (p = 0.007). To determine whether the panel of sCysC plus uNAG can materially improve risk reclassification, we used IDI and the cNRI in this analysis. Addition of sCysC plus uNAG significantly improved the risk reclassification of AKI over the clinical model alone, with the largest cNRI (0.633) and IDI (0.076).
To further confirm the improvement in risk classification with this panel to the clinical risk model, bootstrap internal validation was conducted and demonstrated comparable cNRI (0.638) and IDI (0.079).
Discussion
In this study, we demonstrated that the combination of functional and tubular damage biomarkers (sCysC plus uNAG) presents an effective clinical strategy for predicting AKI after resection of intracranial space-occupying lesions. To our knowledge, this is the first study that prospectively evaluated the diagnostic accuracy of combining functional and tubular damage biomarkers for AKI prediction in patients undergoing neurosurgery.
Resection of intracranial space-occupying lesions is one of the most common neurosurgical procedures [2, 33, 34] . Development of AKI after neurosurgery is a frequent complication and associated with adverse outcomes [1, 2, 35] . In the present study, postoperative AKI prevalence was 11.1% and was associated with higher rate of mortality, prolonged hospital length of stay, and higher costs. A recent large retrospective study on 1,656 patients undergoing craniotomy [1] showed that the incidence of postoperative AKI was 9.9%, similar to the result found in our cohort, and indicated that occurrence of AKI was a risk factor for postoperative mortality.
Potential biomarkers have been explored for an early recognition of AKI including, but not limited to, urinary matrix metalloproteinase-7 [36] , urinary angiotensinogen [9] , tissue inhibitor of metalloproteinase-2, insulin-like growth factor binding protein 7 [37] , neutrophil gelatinase-associated lipocalin [38] , kidney injury molecule-1 [39] , NAG [8, 40] , CysC [7, 40] , and urinary albumin [7] . However, AKI is a heterogeneous syndrome, and individual biomarkers cannot reflect its multiple pathophysiological processes [41] . Therefore, the ADQI working group recommended combining functional and tubular damage AKI biomarkers, which can reflect different underlying pathological processes of AKI [3] . sCysC and uACR are considered functional biomarkers [7] , while uNAG represents tubular damage [7, 8] . Of note, these biomarkers are clinically available worldwide. Hence, we selected these biomarkers to conduct our investigation based on the hypothesis that renal markers can be classified as those representing tubular damage and those reflecting changes in renal function [3, 7] . Similar to previous studies [40, [42] [43] [44] , the three biomarkers showed poor to moderate AUC-ROC values for AKI prediction in our cohort. Exhilaratingly, the composite of sCysC (functional biomarker) plus uNAG (tubular damage biomarker) was more robust than either the individual biomarkers or the other two combinations. Additionally, we found that the combination of sCysC and uNAG yielded the highest AUC-ROC for predicting AKI within the first 24 h after operation. This combination of sCysC and uNAG measured at ICU admission seems to have relatively different predictive ability for AKI occurring at different times after operation. The possible reason may be that the predictive power of the biomarkers becomes weaker at longer time intervals.
On the one hand, sCysC, produced in all nucleated cells and freely filtered in glomeruli and completely absorbed [8] , is considered a better marker of glomerular filtration rate [8] and a potential biomarker for AKI detection [7, 45] . Increased concentration of urinary albumin indicates increased permeability of the basal membrane of glomerular injury [46] and reflects glomerular structure and function change. Thus, urinary albumin is considered a functional marker for AKI detection [47, 48] . On the other hand, uNAG, produced in proximal and distal tubular cells and nonrenal cells, is too large to undergo glomerular filtration and released into urine after tubular damage. Hence, uNAG is a quite sensitive marker for renal tubule damage [41, 49] . In this study, the combination of uNAG plus sCysC, which includes two markers indicative of different AKI pathophysiological conditions, yielded fairly good performance in predicting AKI. The improved performance of combining functional and tubular damage biomarkers (sCysC and uNAG) in this cohort is in keeping with previous studies in patients undergoing cardiac surgery or suffering from heart failure [4] [5] [6] . Basu et al. [4] showed that a combination of a tubular injury biomarker (urinary neutrophil gelatinase-associated lipocalin) and a functional glomerular damage biomarker (plasma CysC) had additive ability to predict AKI in 345 children undergoing cardiopulmonary bypass surgery. A previous research on 103 adults with acute decompensated heart failure found that combining functional and tubular damage markers (sCysC and urinary kidney injury molecule-1) improved the discriminatory power for AKI detection [6] .
Nevertheless, use of a biomarker composite do not always improve predictive precision. Han et al. [50] found that a composite of tubular injury biomarkers (urinary kidney injury molecule-1 and uNAG) did not enhance diagnostic performance for AKI in children after cardiopulmonary bypass surgery. Similarly, in our cohort, the composite of uNAG plus uACR and the composite of sCysC plus uACR failed to yield additive ability to predict postoperative AKI. One possible explanation is that the former combination included the same source of Deng et al.: Combining Functional and Tubular Damage Biomarkers Predicts Acute Kidney Injury www.karger.com/kbr specimens and the latter included two biomarkers, both indicating glomerular damage and sharing the same mechanism [51] .
Our study has several limitations. First, the study was conducted in a single center, and hence our conclusions have limited generalizability. Additional multicenter cohorts are warranted to verify the efficacy of using these biomarkers to predict postoperative AKI. Second, only one measurement of these biomarkers was used. Repeat measurements may improve the accuracy of assessment. Nevertheless, the ADQI cannot recommend a serial measurement schedule [3] , as it is not practical and cost-effective for a series of sample collecting and measuring. We speculate that our findings are not debilitated by this limitation. Third, there may be a certain link between brain dysfunction and kidney disease [52] . A recent report indicated that AKI was associated with impaired cognition in children with severe malaria [53] . In our department we did not routinely evaluate the cognitive ability by the Mini-Mental State Examination or the Montreal Cognitive Assessment. We will discuss the association between AKI and cognitive ability impairment in future study. Additionally, the GCS score was reported to be an independent risk factor for AKI in previous study [54] . Hence, we included preoperative GCS score, postoperative GCS score, and change in GCS score from first post-to preoperative check in logistic regression for AKI prediction. In the present study, the postoperative GCS score was the independent risk factor for postoperative AKI. Last but not least, statistical power to detect the effect of AKI on mortality was limited due to a small number of events.
In conclusion, the present study demonstrates that combining functional and tubular damage biomarkers (sCysC plus uNAG) is a reasonable strategy to improve the discriminative performance for AKI prediction in patients undergoing resection of intracranial space-occupying lesions. This study was conducted in patients who underwent resection of intracranial space-occupying lesions, which is one of the most common neurosurgical procedures. Moreover, these clinically available biomarkers (sCysC, uNAG, and uACR) could be used as routine diagnostic tools in clinical practice. Thus, this study could have significant clinical implications for similar cohorts at risk of AKI. 
